Posttraumatic stress disorder (PTSD) is a frequently occurring and often debilitating anxiety disorder resulting from exposure to trauma. Trauma-focused cognitive-behavioural therapies, such as Eye movement desensitization and reprocessing (EMDR), are generally considered to be evidence-based treatments for PTSD. Although a majority of patients achieve improvement, a substantial minority either drop out of treatment, present with residual symptoms following treatment or fail to make any improvement. Furthermore, a substantial portion of the clinical trials on PTSD is characterised by major methodological limitations. In addition, there's a pressing need for research on mediators of treatment outcome. Taken together, these results highlight the need for methodological rigorous and stringent clinical trials comparing treatment modalities for PTSD. The first aim of this study is to investigate whether a treatment not based on the principles of exposure, i.e. metacognitive therapy (MCT) is as efficient as exposure-based treatments. The second aim to elucidate potential mediators of treatments effects by incorporating process-related variables.
EMDR is based on the assumption that posttraumatic symptoms are due to the traumatic experience(s) being stored in an unprocessed way disconnected from existing memory networks. The procedure in EMDR is postulated to facilitate the processing of the traumatic memory into existing memory networks. There is currently no empirical knowledge as to the therapeutic mechanisms of EMDR, but the protocol overlaps with core components of cognitive behavior therapy (CBT), such as imaginal exposure and cognitive restructuring of negative trauma-related cognitions. Thus, EMDR could be viewed as a form of CBT, although its originator maintains that it is a distinct treatment. EMDR is usually considered an evidence-based treatment of PTSD. MCT is one of the new approaches in the treatment of PTSD. The metacognitive model posits that adaptation following exposure to trauma depends on metacognitive beliefs that guide how the individual interprets and responds to posttraumatic symptoms and can lead to styles of thinking that facilitate or impede emotional processing. MCT focuses on "unlocking" or removing the barriers to natural adaptation. This equips the client with general skills and therefore protects the individual from the risk of any future re-traumatisation. In contrast to EMDR, MCT does not involve proscribed exposure exercises or restructuring of negative trauma-related cognitions. In addition we will include a group of 30 patients matched for age, gender and personality disorders receiving treatment as usual (TaU) in an outpatient setting as a non-randomized comparative control condition.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
96
8-12 sessions of manualized metacognitive therapy
8-12 sessions of manualized EMDR
8-12 sessions of treatment of usual
Outpatient speciality clinic for PTSD and other trauma-related emotional disorders at Østmarka, St. Olav University Hospital
Trondheim, Norway
Posttraumatic Stress Disorder Scale (PDS)
Time frame: 8-12 weeks post-treatment
Posttraumatic Stress Disorder Scale (PDS)
Time frame: 12 month follow-up
Anxiety Disorders Interview Schedule (ADIS-IV)
Time frame: Pre-treatment/baseline; 8-12 weeks post-treatment
PTSD Symptom Scale - Interview (PSS-I)
Time frame: Pre-treatment/baseline; 8-12 weeks post-treatment
Impact of Event Scale - Revised (IES-R)
Time frame: Pre-treatment/baseline; 8-12 weeks post-treatment; 12 month follow-up
Beck Anxiety Inventory (BAI)
Time frame: Pre-treatment/baseline; 8-12 weeks post-treatment; 12 month follow-up
Beck Depression Inventory (BDI-II)
Time frame: Pre-treatment/baseline; 8-12 weeks post-treatment; 12 month follow-up
Metacognitions Questionnaire - 30 (MCQ-30)
Process outcome / mediator measure
Time frame: Pre-treatment/baseline; weekly; 8-12 weeks post-treatment
Posttraumatic Cognitions Inventory (PTCI)
Process outcome / mediator measure
Time frame: Pre-treatment/baseline; weekly; 8-12 weeks post-treatment
Session Rating Scale (SRS)
Process outcome / mediator measure
Time frame: Pre-treatment/baseline; weekly; 8-12 weeks post-treatment
Inventory of Interpersonal Problems (IIP-64-C)
Time frame: Pre-treatment/baseline; 8-12 weeks post-treatment; 12 month follow-up
Posttraumatic Stress Disorder Scale (PDS)
Time frame: Weekly
WHO-5 Well-Being Index
Time frame: Pre-treatment/baseline; 8-12 weeks post-treatment; 12 month follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.